Thyroid Nodules: From Diagnosis to Non-Surgical Treatment

A thyroid nodule is a mass within the thyroid gland that is distinct from the tissue around it. It is far more common than people assume: the 2023 European Thyroid Association nodule guideline states that, with the spread of sensitive imaging, up to 60% of adults are found to harbour one or more thyroid nodules.

The great majority of these are benign, cause no complaints and require no treatment. Most are also found incidentally, during an examination or a scan done for another reason.

For that reason, "I have a nodule" is not in itself a diagnosis of disease. The real questions are: does this nodule look suspicious, does it cause a complaint, does it disturb the hormone balance?

Blood tests show how the thyroid is working; they do not show whether a nodule is present. TSH, and other hormone levels when needed, are requested to see whether the gland is over- or under-active.

The method that shows the nodule itself is ultrasound. It assesses the size of the nodule, whether it is solid or fluid, its margins, any microcalcifications within it and its vascularity. These features are placed into a risk category using scoring systems such as ACR TI-RADS.

The decision to biopsy comes from reading that risk category together with the size — so not every nodule is biopsied. When a biopsy is needed it is done with a fine needle while watching the ultrasound screen, and the needle is confirmed on the image to be inside the nodule. The result is reported in a shared language called the Bethesda system.

Treatment decisions fall under three headings. The first is nodules shown to be malignant, or with a high probability of being so; their plan is separate.

The second is benign nodules that cause complaints because of their size: visible fullness in the neck, a sense of catching on swallowing, breathlessness or voice change.

The third is nodules producing excess hormone (functioning autonomously); these can cause palpitations, weight loss and sweating, and their treatment aims to reduce hormone production.

For benign nodules outside these three headings — causing no complaints and stable on follow-up — surveillance is as a rule sufficient. Surveillance is not a postponement; it is a treatment decision in its own right.

Surgery remains the established treatment; but image-guided non-surgical methods have become an option in selected nodules. Their shared logic is this: a fine needle is placed inside the nodule under ultrasound guidance, the target tissue is destroyed in place, and the healthy thyroid tissue around it is preserved.

The heat-based methods are radiofrequency ablation, microwave ablation and laser ablation. The 2020 European Thyroid Association guideline states that laser and radiofrequency are the most thoroughly assessed and give similarly satisfactory results, while the evidence for microwave and high-intensity focused ultrasound (HIFU) has not yet fully matured.

In predominantly fluid nodules a different route is taken instead of heat: the fluid is drained and ethanol ablation is then performed. In mixed nodules a two-step plan can be built.

These procedures are performed under local anaesthesia, general anaesthesia is not required, and the patient usually goes home the same day.

No. No incision is made in the skin; only an entry point the width of a needle passes through it. For that reason no wound scar of the kind seen after surgery forms.

Because the neck is hard to cover with clothing and highly visible, this detail is a genuine part of the decision for many patients; it is not a trivial heading.

The points of difference are these: there is no incision and no surgical scar, general anaesthesia is not required, no hospital stay is expected, and after a short observation the patient returns to daily life.

In the treatment of benign nodules the healthy tissue outside the nodule is preserved, so the thyroid hormone balance is usually unaffected; the lifelong hormone medication needed after removal of the whole thyroid is as a rule not required on this route.

Two points must be stated plainly in return. Because tissue is not removed, no pathological examination is possible — which is why a biopsy beforehand is essential. And the nodule does not disappear at once; shrinkage proceeds gradually over months, and a small remaining residue can grow again over the years. Regular follow-up is therefore part of the treatment.

On the first day it is advised not to press on the treated area, not to massage it firmly, and to avoid heavy physical activity. Tenderness, mild swelling and bruising in the neck lasting a few days are expected findings.

If there is pain, the analgesic your physician recommends may be used; a cold pack also helps. Eating soft, lukewarm food in the first days is more comfortable for most patients.

If redness, rapidly increasing swelling, fever or an unexpected change in the voice occurs, contact your physician without delay. Keeping to the scheduled check-ups is the single most important heading.

The thyroid sits in a very narrow space, neighbouring the nerve that supplies the vocal cord, the oesophagus and large vessels. The safety of the procedure therefore depends on keeping the needle tip continuously visible on ultrasound and, where needed, creating a safety margin by injecting fluid between the target and the neighbouring structure (hydrodissection).

Guidelines put numbers to that expectation. The 2024 Chinese guideline on ultrasound-guided thermal ablation of thyroid nodules expects the operator to have more than three years of thyroid ultrasound experience, more than two hundred ultrasound-guided thyroid biopsies, and the ability to keep the needle tip continuously visible throughout. This criterion is sometimes quoted as if it came from the American Thyroid Association; its source is the Chinese guideline named here.

The great majority of nodules are benign and pose no serious threat to health. A small proportion may be malignant; this is why the ultrasound appearance and, where needed, a biopsy are used to assess them.

The second dimension of the danger question is size: even a benign nodule, if large, can press on the trachea or the oesophagus, or affect metabolism by producing hormone. A "benign" result therefore does not mean follow-up is unnecessary.

Early assessment protects against both unnecessary intervention and delay. What matters is discussing the features of the nodule, not merely its existence.

Generally no. In benign nodules causing no complaints, surveillance rather than medication is preferred. Giving thyroid hormone in order to shrink a nodule is not a recommended approach today.

The exception is nodules producing excess hormone; there, medication that suppresses hormone production can be part of treatment, though a different method is often needed for a lasting solution.

In malignant nodules, or in large nodules causing pressure, medication is not an option; in those situations surgery, or an image-guided procedure in suitable patients, comes into play.